Bionano lowers Q3 revenue guidance to $6.5-6.8M from $7.9-8.9M; cash $23.3M

Bionano Genomics, Inc.

2024-Q3 EPS reported -$1.34 revenue$22,613,000

Preliminary Q3 revenue $6.5-6.8M, down from prior guidance of $7.9-8.9M.
Cash and restricted cash ~$23.3M as of Sep 30; $11.4M restricted.
Revenue miss driven by strategic shift away from new OGM system placements and sector headwinds.
Potential material impairments and charges pending completion of end-of-period review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.